First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque-type Psoriasis

Interventions

DRUG: secukinumab 150 mg
DRUG: secukinumab 300 mg
DRUG: placebo

Sponsor

Novartis Pharmaceuticals